Studybox Research CLIA Waiver Studies

Bacterial Vaginosis Point-of-Care Test

Accuracy in the hands of untrained intended-use operators at waived sites.

Studybox

CLIA Waiver Studies

Bacterial vaginosis is the most common cause of vaginal discharge in reproductive-age women, and its reference standards are old: the Amsel clinical criteria at the bedside and the Nugent Gram-stain score in the laboratory. Neither is perfect, the Nugent score includes an intermediate category, and point-of-care tests have been compared to one or both with pre-specified rules for intermediates. The clinical study enrolls symptomatic women, collects the device swab alongside a smear for Nugent scoring and the Amsel components, and reports performance against the chosen reference.

Because the reference depends on trained microscopy readers, central reading of Gram stains with documented inter-reader agreement is a standard element, and Amsel documentation at the visit has to be standardized across sites that may not routinely perform pH or whiff testing. Intended use is typically restricted to symptomatic women, since asymptomatic BV has uncertain clinical significance and the reference performs differently in that population.

Analyte: Markers of bacterial vaginosis: sialidase enzyme activity, vaginal pH and amines, or nucleic acid of BV-associated bacteria, depending on the device
Therapeutic area: Women's Health
Specimens: Vaginal Swab
Intended-use settings: physician office, urgent care, emergency department
Operators: Clinicians and non-laboratory staff in physician offices and urgent care centers with waived certificates; laboratory staff for moderate-complexity claims.
Comparator: Typically Nugent scoring of a Gram-stained vaginal smear by trained readers, with Amsel clinical criteria recorded at the visit; the protocol specifies how intermediate Nugent scores are classified.

CLIA Waiver Studies specifics

What Changes for This Assay on This Pathway.

Enzyme-activity and pH-based devices are visually read, and flex studies typically stress swab expression, incubation time and temperature, read time and interpretation of color change under clinic lighting.
Waived operators are clinic staff who may also collect the swab during an exam; the protocol should document that the operator running the device is untrained in laboratory methods, even if clinically skilled.
If self-collected swabs are claimed for waived use, the waiver study should include them, since specimen quality from self-collection is part of the system.

Endpoints the study must support

Sensitivity and specificity against Nugent score (and against Amsel criteria where pre-specified), with 95% confidence intervals, in symptomatic women
Transparent handling of intermediate Nugent scores, with analyses excluding and including them
Agreement between self-collected and clinician-collected swabs where both are claimed, and invalid rate in waived settings

Enrollment realities

Driven by Nugent-positive symptomatic women, who are a substantial share of women presenting with discharge, so accrual is faster than for most STI tests; intermediate Nugent results and inadequate smears are predictable losses.

How Studybox runs it

Pre-Qualified Sites, Embedded Coordinators.

Waiver evidence depends on genuine intended-use operators in genuine waived settings. Our network of 100+ pre-qualified urgent care, physician office, and point-of-care sites already runs IVD protocols, so operator recruitment and site activation don't start from zero. How we run clia waiver studies →

Same assay, other pathways

Relevant FDA guidance

FAQ

Bacterial Vaginosis Point-of-Care Test Study Questions.

01 Who operates the bacterial vaginosis point-of-care test in a clia waiver studies study?

Clinicians and non-laboratory staff in physician offices and urgent care centers with waived certificates; laboratory staff for moderate-complexity claims.

02 What is the comparator for a bacterial vaginosis point-of-care test study?

Typically Nugent scoring of a Gram-stained vaginal smear by trained readers, with Amsel clinical criteria recorded at the visit; the protocol specifies how intermediate Nugent scores are classified.

03 What drives enrollment for a bacterial vaginosis point-of-care test study?

Let's talk IVD research

Planning a bacterial vaginosis point-of-care test study?

Tell us the intended use and setting. We'll come back with a site plan, operator strategy, and a realistic activation timeline for the clia waiver studies pathway.